Pelvic Health

New Campaign: Sexual Wellness Brand HANX Wants You to “Open Up” about Vaginismus

Sexual wellness brand HANX has launched a new campaign called “Let’s Open Up” to raise awareness about vaginismus. The condition can make sexual activities, but also tampon use or pap-smears painful or even impossible. Last week HANX used Valentine’s Day as an opportunity to help people with vaginas have open conversations about vaginismus. Although vaginismus affects as many people as erectile dysfunction,…

FDA Grants 510(k) Clearance to the Perifit Kegel Exercise Device

The Perifit device has recently received 510(k) clearance from the United States Food and Drug Administration (FDA). Developed by a Paris-based company, Perifit has been designed to help women improve their pelvic floor muscle strength, while also providing an interactive experience with mobile games. The Perifit device is a small, connected device that is inserted into the vagina, and acts as a…

Axena Health Secures $25M Series A Investment to Accelerate Global Adoption of Leva, Its Digital Health Treatment for Female Incontinence

Axena Health, a medical device company focused on women’s pelvic health, has received a $25M investment from AXA IM Alts through its Global Healthcare Private Equity Strategy. The investment will support the expansion of access to the Leva Pelvic Health System, a prescription digital therapeutic for the treatment of urinary incontinence and chronic fecal incontinence in women. The Leva System has been…

Rejoni Raises $25M in Series B Funding for Its Hydrogel System to Prevent Intrauterine Adhesions Following Transcervical Gynecological Procedures

Medtech company Rejoni has raised $25M in Series B funding from Catalyst Health Ventures. Other investors in the round include Ascension Health Ventures, Delos Capital, Sparta Group, Amed Ventures, and Iyengar Capital Partners. Rejoni raised its $15M Series A in September 2020. Rejoni is a privately held medical technology company designing and developing hydrogels to improve the standard of care in Women’s Health. Rejoni’s…

Medtech Company FEMSelect Raises a $9M Series B for Its Minimally Invasive Approach to Pelvic Floor Ligament Fixation

FEMSelect, developer of EnPlace, a minimally invasive, meshless approach to pelvic floor ligament fixation, has raised $9M Series B funding led by New Age Ventures and co-led by TriVentures. Other participants in the round include Robin Hood Ventures, Mid Atlantic Bio Angels (MABA), MEDA Angels, Keiretsu Forum Mid-Atlantic, RAD BioMed, Keiretsu Capital and Transpacific Venture Partners. FEMSelect’s EnPlace system’s approach is cleared by the FDA…

Urolon, A New Treatment for Female Stress Urinary Incontinence, Launches in the UK

Stress Urinary Incontinence (SUI) is the most common type of urinary incontinence. According to estimations around 1 in 3 women will experience bladder leakage at some point in their life. SUI happens when the sphincter muscle that controls the urethra, the pelvic floor tissues and muscles that are used to keep the urethra closed, weakens. Urolon developed by Netherlands-based AQLANE Medical, is…

Renovia Receives FDA clearance for Its Pelvic Health System as First-line Treatment for Chronic Fecal Incontinence

Renovia, a developer of non-surgical, treatments for female pelvic floor disorders and an advocate for women’s health, announced today that the U.S. Food and Drug Administration (FDA) has cleared its leva Pelvic Health System for the first-line treatment of chronic fecal incontinence (FI) in women. The decision follows the grant of Breakthrough Device Designation by FDA in October 2021. leva had previously been cleared by FDA to…

New Survey by Hologic Reveals Lack of Knowledge among U.S. Women about Uterine Health

A new survey commissioned by women’s health company Hologic revealed a lack of awareness among U.S. women about uterine health, including uterine fibroid symptoms and treatment options. The company is also launching Hey, U!, a educational campaign focused on uterine health. Uterine fibroids are very common, affecting up to 80% of women by the age of 50. Even so, Hologic’s survey found that 48%…